Reports
Sale
Global Antibody Drug Conjugates Market Size, Share, Forecast: By Product Type: Adcetris, Kadcyla, Other Product Types; By Applications: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, Other Application; By Target Type: CD30 Antibodies, Others: By End User: Regional Analysis; Supplier Landscape; 2024-2032
Global Antibody Drug Conjugates Market Outlook
The global antibody drug conjugates market size was valued at USD 7.96 billion in 2023, driven by the increasing awareness among government and realizing the potential of antibody drug conjugates across the globe. The market size is anticipated to grow at a CAGR of 17.1% during the forecast period of 2024-2032 to achieve a value of USD 32.97 billion by 2032.
Antibody Drug Conjugates: Introduction
Antibody-drug conjugates are a cutting-edge therapeutic approach that combines the distinct, high specificity, properties, and anti-tumour activity of monoclonal antibodies (mAbs), which are tumour-specific but insufficiently cytotoxic, with the potent cell-killing activity of highly cytotoxic small molecules that are inappropriate for systemic administration alone. Because these compounds have the ability to deliver highly cytotoxic payloads directly to tumour cells, they can be employed to achieve great lethality towards the targeted cancer cells while sparing healthy cells.
A new form of extremely powerful biopharmaceutical medication known as an "antibody-drug conjugate," or ADC, consists of an antibody coupled to a biologically active drug or cytotoxic substance via a chemical linker. These targeted medicines combine the particular and acute targeting characteristics of antibodies, enabling sensitive differentiation between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.
Global Antibody Drug Conjugates Market Analysis
The market for antibody drug conjugates has been witnessing significant growth and is expected to keep growing in the coming years as well due to various trends going on in the market currently. Antibody drug conjugates are used in the treatment of cancer but there are some attempts that have been made to expand the application of ADCs to different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. The research to expand the applications is currently in progress and soon will be releasing outcomes, further expected to fuel the market growth.
LegoChem Biosciences is the key player in the market and is a major ADC developer with 25 drug candidates in development, expected to further drive the market growth. Despite, most of its pipeline assets are in the preclinical phase. The most advanced drug by LegoChem Biosciences is in Phase II clinical trials. With the most advanced portfolio, Seagen has five launched products and seven clinical-stage candidates, propelling the global antibody drug conjugates market growth.
Pfizer has announced a major investment of USD 43 billion in cash to acquire ADC pioneer Seagen Inc. The US big pharma was pulled towards four of the approved products of Seagen’s, out of which three ADCs and a small-molecule cancer drug along with other candidates in its pipeline. The expected annual revenue generated out of this purchase is USD 10bn by 2030, further propelling the market growth.
Chief Executive Officer at ImmunoGen, Inc. Enyedy exhibited the company’s partnership with MacroGenics, Inc. The collaborating companies are co-developing IMGC936 as a first-in-class ADAM9-targeting ADC. ADAM9 is a cell surface protein from the ADAM (a disintegrin and metalloproteinase) family of proteases, which has been implicated in cytokine and growth factor shedding and cell migration. It has been shown that ADAM9 is overexpressed in multiple solid tumor types (eg, non-small cell lung cancer, gastric, pancreatic, triple-negative breast and colorectal) and minimally expressed on normal tissue. IMGC936 is being tested in Phase I studies, contributing to the antibody drug conjugates market growth.
Additionally, BioNTech SE has also made and important announcement regarding exclusive license and collaboration agreements with DualityBio for two antibody-drug conjugate assets to develop and commercialize globally (excluding some Asian markets). DualityBio is expected to receive USD 170m, as well as potential development, regulatory and commercial milestone payments for both assets, totaling more than USD 1.5 billion, expected to further escalate the market expansion.
Global Antibody Drug Conjugates Market Segmentations
Market Breakup by Product Type
- Adcetris
- Kadcyla
- Other Product Types
Market Breakup by Applications
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumour
- Other Application
Market Breakup by Target Type
- CD30 Antibodies
- HER2 Antibodies
- Other Target Types
Market Breakup by End User
- Hospitals and Specialty Cancer Centers
- Biotechnology and Pharmaceutical Companies
- Other End Users
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Antibody Drug Conjugates Market Overview
The market is experiencing significant market growth due to the increasing prevalence of cancer among people globally. The rising incidence of breast cancer worldwide is also contributing to the market growth. The major factors responsible for the growth of the antibody-drug conjugates market include the increasing geriatric population along with the rising research and development activities for the development of innovative treatments. Antibody-drug conjugates are believed to provide the most effective treatments to cancer patients. The lifetime probability of being diagnosed with invasive cancer is slightly higher for men (40.9%) than for women. Higher risk in men for most cancer types is thought to largely reflect greater exposure to carcinogenic environmental and behavioural factors, such as smoking, consuming alcohol, among other factors.
Geographically, North America has the highest cases of cancer, and the increasing number of cancer cases is contributing to the market growth in the region. The presence of some key players of the market aiding the antibody drug conjugates market share in the region.
In total, there will be approximately 1,958,310 new cancer cases, the equivalent of about 5370 cases each day. In addition, there will be about 55,720 new cases of ductal carcinoma in situ in women and 89,070 new cases of melanoma in situ of the skin, further increasing the demand for antibody drug conjugates.
Antibody Drug Conjugates Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Seagen Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- AbbVie Inc.
- Takeda Pharmaceutical Company Ltd
- AstraZeneca PLC
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Applications |
|
| Breakup by Target Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Antibody Drug Conjugates Market Overview
3.1 Global Antibody Drug Conjugates Market Historical Value (2017-2023)
3.2 Global Antibody Drug Conjugates Market Forecast Value (2024-2032)
4 Global Antibody Drug Conjugates Market Landscape
4.1 Global Antibody Drug Conjugates: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Antibody Drug Conjugates: Product Landscape
4.2.1 Analysis by Isotope
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Antibody Drug Conjugates Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Antibody Drug Conjugates Market Segmentation
6.1 Global Antibody Drug Conjugates Market by Product Type
6.1.1 Market Overview
6.1.2 Adcetris
6.1.3 Kadcyla
6.1.4 Other Product Types
6.2 Global Antibody Drug Conjugates Market by Applications
6.2.1 Market Overview
6.2.2 Blood Cancer
6.2.3 Breast Cancer
6.2.4 Ovary Cancer
6.2.5 Lung Cancer
6.2.6 Skin Cancer
6.2.7 Brain Tumor
6.2.8 Other Application
6.3 Global Antibody Drug Conjugates Market by Target Type
6.3.1 Market Overview
6.3.2 CD30 Antibodies
6.3.3 HER2 Antibodies
6.3.4 Other Target Types
6.4 Global Antibody Drug Conjugates Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Specialty Cancer Centers
6.4.3 Biotechnology and Pharmaceutical Companies
6.4.4 Other End Users
6.5 Global Antibody Drug Conjugates Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Antibody Drug Conjugates Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Antibody Drug Conjugates Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Antibody Drug Conjugates Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Antibody Drug Conjugates Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Antibody Drug Conjugates Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Seagen Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 ImmunoGen Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Mersana Therapeutics Inc.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 F. Hoffmann-La Roche Ltd
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Sorrento Therapeutics Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Oxford BioTherapeutics Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 AbbVie Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Takeda Pharmaceutical Company Ltd
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 AstraZeneca PLC
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 7.96 billion in 2023, driven by the reliability it provides.
The market is anticipated to grow at a CAGR of 17.1% during the forecast period of 2024-2032, likely to reach a market value of USD 32.97 billion by 2032.
The rising prevalence of cancer, especially breast cancer, is driving the market growth.
The increasing collaborations and investments made by the key players in the market is the major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
They find wide applications in blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumour, among other applications.
Target types involved are CD30 antibodies and HER2 antibodies, among other target types.
The end users are hospitals and specialty cancer centers, biotechnology and pharmaceutical companies, among other end users.
Key players involved in the market are Seagen Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, AbbVie Inc., AstraZeneca PLC., and Takeda Pharmaceutical Company Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER